Now That's the Way to Spin Off a Company

Spin-offs can bring some serious added value to a company. The idea that the individual parts of a company are worth more than when they're combined may sound counterintuitive to some, but it can actually be true.

Witness the old Abraxis BioScience -- half biotech one-drug wonder, half generic-drug maker. When the company broke apart last November, investors were valuing the centaur of the drug world at just $3.5 billion. Now, the two separate companies, APP Pharmaceuticals (Nasdaq: APPX  ) and Abraxis BioScience (Nasdaq: ABII  ) , are together worth more than $6 billion. I'd call that a successful spin-off.

But part of that value comes from German company Fresenius and its announcement yesterday of plans to purchase APP Pharmaceuticals for $23 per share -- a 29% premium over the previous closing price. (Before the announcement, the duo was worth about $5.3 billion -- still successful.)

Investors in the purchased generic-drug company could see even more money headed their way. APP Pharmaceuticals will remain a stand-alone company, and if certain targets are met, investors will be entitled to up to an additional $6 per share payable in the second quarter of 2011.

The synergies between APP Pharmaceuticals and Fresenius are pretty good, too. The merger will allow APP Pharmaceuticals to sell its generic-injectable drugs globally without huge start-up costs, and Fresenius gets a foot in the lucrative U.S. generic-drug market. Not a bad deal.

With foreign drug companies snatching up their American counterparts, it's fun to speculate which stateside generic-drug companies might be next. Hospira (NYSE: HSP  ) , a 2004 spin-off of Abbott Labs (NYSE: ABT  ) , might be a takeover target, as could small generic-drug companies like Watson Pharmaceuticals (NYSE: WPI  ) or Par Pharmaceutical (NYSE: PRX  ) .

The potential for takeover isn't a reason to invest in these companies, but, as APP Pharmaceuticals' investors have found out, it sure is a nice added bonus.

More Foolishness on foreign drug companies coming stateside:

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

DocumentId: 680462, ~/Articles/ArticleHandler.aspx, 4/19/2014 2:20:36 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASD 4,095.52 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/9/2008 4:00 PM
APPX $23.70 Down +0.00 +0.00%
Abraxis BioScience… CAPS Rating: **
ABII.DL $0.00 Down +0.00 +0.00%
Abraxis BioScience… CAPS Rating: *****
ABT $38.93 Up +0.55 +1.43%
Abbott Laboratorie… CAPS Rating: *****
ACT $197.39 Down -1.99 -1.00%
ACTAVIS CAPS Rating: ***
HSP $42.84 Down -0.16 -0.37%
Hospira, Inc. CAPS Rating: ***
PRX $0.00 Down +0.00 +0.00%
Par Pharmaceutical… CAPS Rating: ***

Advertisement